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Background: First trimester Pregnancy Associated Plasma Protein A (PAPP-A) levels, routinely measured for
aneuploidy screening, may predict development of preeclampsia. This study tests the hypothesis that first trimester
PAPP-A levels correlate with soluble fms-like tyrosine kinase-1 (sFlt-1) levels, an angiogenic marker associated with
preeclampsia, throughout pregnancy.
Methods: sFlt-1 levels were measured longitudinally in 427 women with singleton pregnancies in all three
trimesters. First trimester PAPP-A and PAPP-A Multiples of Median (MOM) were measured. Student’s T and Wilcoxon
tests compared preeclamptic and normal pregnancies. A linear mixed model assessed the relationship between log
PAPP-A and serial log sFlt-1 levels.
Results: PAPP-A and PAPP-A MOM levels were significantly lower in preeclamptic (n = 19), versus normal
pregnancies (p = 0.02). Although mean third trimester sFlt-1 levels were significantly higher in preeclampsia
(p = 0.002), first trimester sFlt-1 levels were lower in women who developed preeclampsia, compared with normal
pregnancies (p = 0.03). PAPP-A levels correlated significantly with serial sFlt-1 levels. Importantly, low first trimester
PAPP-A MOM predicted decreased odds of normal pregnancy (OR 0.2, p = 0.002).
Conclusions: Low first trimester PAPP-A levels suggests increased future risk of preeclampsia and correlate with
serial sFlt-1 levels throughout pregnancy. Furthermore, low first trimester PAPP-A status significantly predicted
decreased odds of normal pregnancy.Background
Preeclampsia affects approximately 5% of all pregnancies
and remains a significant cause of maternal and neonatal
morbidity and mortality [1]. Early risk stratification may
improve the identification of women at highest risk for
preeclampsia and provide an opportunity for interven-
tion [2]. Thus far, several markers have been evaluated
regarding their ability to predict preeclampsia in the first
trimester, prior to clinical onset of clinical signs. How-
ever, the accuracy of these markers are suboptimal for
clinical use [3,4]. Pregnancy associated Plasma Protein A
(PAPP-A) levels are measured in clinical practice for the
1st trimester aneuploidy screen, as low levels indicate* Correspondence: asaxena@partners.org
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reproduction in any medium, provided the orincreased risk for trisomy 13, 18, 21 [5]. Emerging data
support that preeclampsia and other pregnancy compli-
cations are also associated with low PAPP-A levels [6,7].
Soluble fms-like tyrosine kinase 1 (sFlt-1) is a circulating
antagonist to vascular endothelial growth factor (VEGF)
and an anti-angiogenic factor in placentation. Although
not routinely applied in clinical settings, sFlt-1 levels are
markedly increased in the second and third trimesters in
cases of preeclampsia. Furthermore, the rise in sFlt-1
precedes the onset of clinical signs of preeclampsia [8].
As both PAPP-A and sFlt-1 may predict increased risk
for preeclampsia, in this study we explore the relation-
ship of 1st trimester PAPP-A levels, which are obtained
routinely for clinical care, with serial levels of sFlt-1,
a widely accepted marker of preeclampsia in research,
and test the hypothesis that 1st trimester PAPP-A corre-
lates with serial sFlt-1 levels throughout pregnancy. InLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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serial levels of placental growth factor (PlGF) and serial
ratios of sFlt-1 to PlGF were also explored, as studies
have shown that PlGF is significantly lower in preeclampsia
[9] and the ratio of sFlt-1/PlGF is also significantly elevated
in preeclampsia [10,11], prior to the onset of clinical signs.
Methods
Study population
In this nested case-control study, study participants
(n = 427) were chosen from a prospectively collected,
longitudinal cohort of pregnant women, initiating prena-
tal care between October 2006 and September 2008 at
Brigham and Women’s Hospital in Boston, MA. This hos-
pital served as one of three study sites for a larger study to
explore the utility of angiogenic markers in early diagnosis
of preeclampsia [4]. Blood was drawn from subjects
at four clinical visits during pregnancy: at 8–10 weeks
estimated gestational age (EGA), 17–19 weeks EGA,
23–25 weeks EGA, and 34–35 weeks EGA. Pregnancy
related diagnoses were abstracted from medical records. A
panel of expert obstetricians confirmed the diagnosis of
preeclampsia by review of medical records, using Working
Group criteria [12]. These experts were blinded to the
angiogenic factor and PAPP-A measurements for each
subject. Subjects were eligible for inclusion in the study if
they were a minimum of 18 years of age and pregnant with
an estimated gestational age less than or equal to 15 weeks.
This study received approval from the Institutional Review
Board at Brigham and Women’s Hospital. Subjects signed
consent prior to initiation of study directed activities.
For this analysis, participants were included if they
had completed a 1st trimester screening with PAPP-A
and human chorionic gonadotropin (hCG) levels and
were later diagnosed with either preeclampsia or normal
pregnancy. Women with other pregnancy complications,
such as gestational hypertension, gestational diabetes, or
preterm delivery without the diagnosis of preeclampsia,
were not included in this analysis. Subjects were excluded
if they had any medical diagnoses prior to pregnancy,
including diabetes or hypertension prior to pregnancy,
with the exception of use of thyroid medication. Subjects
were also excluded if they required in vitro fertilization to
achieve pregnancy. Race was self-defined. Smoking status
was self-reported.
Study methods
In each woman, body mass index (BMI), mean arterial
pressure (MAP), plasma sFlt-1 levels, and plasma levels
of placental growth factor (PlGF) were measured at four
clinical visits during pregnancy, at time points described
earlier. PAPP-A and hCG levels were obtained in each
woman as part of their 1st trimester screening. There
were no cases of aneuploidy in this cohort. Gestationalage was confirmed by ultrasound prior to 15 weeks ges-
tation. Gestational age at delivery and birth weight were
abstracted from medical records.
Laboratory assays
Specimens were processed within 4 hours of venipuncture
in a refrigerated centrifuge and stored at −80°C until ana-
lysis. sFlt-1 and PlGF were measured using prototype
ARCHITECT immunoassays (Abbott Laboratories, Abbott
Park, IL), which are chemiluminescent microparticle im-
munoassays. The sFlt-1 immunoassay has a lower limit of
detection of 0.10 ng/mL, ranging to 150 ng/mL. The intra-
and interassay coefficients of variation (CV) were less than
7%. The PlGF immunoassay has a lower limit of detection
of 1 pg/mL with a range up to 1,500 pg/mL. The com-
bined intra- and interassay coefficients of variation (CV)
were less than 7%.
PAPP-A and total hCG levels were obtained from the
patients’ clinical records. Tests were performed at Women
and Infants Hospital, Providence, RI. PAPP-A levels were
measured by ELISA (Diagnostic Systems Laboratories/
Beckman Coulter, Webster, TX), with reported sensitivity
of 0.21μIU/mL and CV 3.6% (Palomaki 2007). Total hCG
levels were measured on the Immulite (Siemens, Los
Angeles CA) with reported sensitivity of 0.23 mIU/mL
and CV 5% (Palomaki 2007). Multiples of median (MOM)
were reported and adjusted for gestational age, maternal
weight and race.
Statistical analysis
Age, parity, 1st trimester BMI, race, and MAP in each tri-
mester were demographic variables of interest. Age, parity,
BMI, and MAP were continuous variables, whereas race
was treated as a categorical variable. The Shapiro-Wilk
Test was used to test for normal distribution. The
Student’s T test was used for two-group comparisons be-
tween women with normotensive pregnancy and women
with preeclampsia. For non-normally distributed data, the
Wilcoxon Rank Sum test was used. Data are expressed as
mean ± standard deviation (SD) or median (interquartile
range) for non-normally distributed data. Non-normally
distributed data were log-transformed for correlation. For
calculation of sFlt-1/PlGF ratio, sFlt-1 levels were first
converted to pg/mL and then expressed as a ratio to mea-
sured PlGF levels [13]. The z-score of the birthweight was
calculated as ([infant birthweight-mean of birthweight
at same weeks EGA]/standard deviation of mean) [14].
Unadjusted correlation of log PAPP-A MOM to serial
levels of log sFlt-1 was performed individually by calcula-
tion of Pearson’s correlation coefficient. To determine
effect of PAPP-A MOM on log sFlt-1, PAPP-A MOM
levels were dichotomized (≥ or < the median PAPP-A
MOM). Logistic regression was used to determine the
ability of dichotomized PAPP-A MOM to predict normal
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ratios (OR) are expressed as OR, [95% confidence inter-
val]. A p-value of less than 0.05 was significant. Analyses
were performed using JMP version 9.0.0 (SAS Institute,
Inc. Cary, NC).Results
Subject demographics
The total number of subjects selected for this analysis
was 427. Nineteen women developed preeclampsia, and
408 women were classified with normal, uncomplicated
pregnancy (Table 1). There were no significant differences
between women with preeclampsia and women with nor-
mal pregnancy with respect to age, parity, or self-reported
smoking. EGA was lower in women with preeclampsia,
but this difference did not reach statistical significance.
The two groups did differ significantly in racial distribu-
tion, first trimester BMI, and MAP obtained during each
trimester (Table 1). Women who developed preeclampsia
had a lower prevalence of Caucasian race and higher
prevalence of African-American race. These women also
demonstrated higher first trimester BMI and higher MAP
in all trimesters of pregnancy.First trimester markers and subsequent pregnancy outcome
Both measured PAPP-A levels and PAPP-A MOM levels
were significantly lower in the first trimester in womenTable 1 Demographic characteristics of study population
Characteristics Preeclamptic
pregnancies
(n = 19)
Normal
pregnancies
(n = 408)
p-value
Age, years 32 ± 7 31 ± 6 0.7
Parity 0.8 ± 0.9 0.9 ± 1.0 0.9
Race
Caucasian 9 (47%) 243 (60%) x2 = 10.3,p = 0.04
African-American 7 (37%) 51 (13%)
Asian 0 20 (5%)
Hispanic 3 (16%) 75 (18%)
Unknown/Other 0 19 (5%)
Any smoking during
pregnancy
3 (16%) 27 (7%) 0.3
First trimester BMI, kg/m2 29.5 ± 6.4 25.2 ± 5.1 p = 0.001
First trimester MAP,
mmHg
84 ± 9 79 ± 7 p = 0.02
Second trimester MAP,
mmHg
83 ± 11 77 ± 8 p = 0.006
Third trimester MAP,
mmHg
85 ± 24 80 ± 8 p = 0.0008
EGA at delivery, weeks 38.5 ± 2.1 39.4 ± 1.2 p = 0.08
Data presented as means ± SD, or N (%).
BMI body mass index; MAP, mean arterial pressure; EGA, estimated
gestational age.who later developed preeclampsia, compared with women
with normal pregnancy (Table 2). Measured hCG levels
and hCG MOM levels did not differ significantly between
the two groups.
Association of dichotomized PAPP-A MOM with
pregnancy outcome
To explore further the significance of low 1st trimester
PAPP-A levels, PAPP-A MOM levels were dichotomized
as low (< median) or high (≥ median). A majority of
women who developed preeclampsia (n = 15 or 83%) were
categorized as low PAPP-A. In contrast, women with nor-
mal pregnancy were more evenly distributed between the
two groups, with 48% classified as low PAPP-A (n = 195)
and 52% characterized as high PAPP-A (n = 213).
Using logistic regression adjusted for first trimester
BMI, women who had lower than median PAPP-A MOM
(LowPAPPAMOM) had decreased odds of having a nor-
mal pregnancy, OR 0.2, [0.04, 0.6], p = 0.002. Conversely,
women with ≥median PAPP-A (HighPAPPAMOM), had
significantly increased odds of having a normal pregnancy,
OR 5.5, [1.8, 24.3], p = 0.002.
Serum angiogenic markers and subsequent
pregnancy outcome
Serum sFlt-1 levels obtained in the 1st trimester were
significantly lower in women who later developed pre-
eclampsia, compared with women with normal preg-
nancy, and did not differ significantly at 17–19 weeks or
at 23–25 weeks between the two groups (Table 3). How-
ever, at 34–35 weeks, sFlt-1 levels were significantly
higher in women who developed preeclampsia. In con-
trast, PlGF levels appeared to be higher in the 1st trimester,
and lower at 17–19 weeks, 23–25 weeks, and 34–35 weeks
in women who later developed preeclampsia, compared
with women with normal pregnancy, however these differ-
ences did not reach statistical significance. The sFlt-1/PlGF
ratio varied between the groups throughout pregnancy. In
the first trimester, the sFlt-1/PlGF ratio was significantly
lower in women who later developed preeclampsia, com-
pared to women with normal pregnancy. There were no
differences in sFlt-1/PlGF ratio between the two groups at
17–19 weeks or 23–25 weeks. However, at 34–35 weeks,Table 2 First trimester markers and pregnancy outcome
Marker Preeclamptic
pregnancies
(n = 19)
Normal
pregnancies
(n = 408)
p-value
PaPP-A, mIU/mL 2.3 (1.33–3.31) 2.8 (1.9–4.2) 0.04
PAPP-A MOM 0.9 (0.7–1.0) 1.1 (0.8–1.4) 0.02
HCG, IU/mL 70.6 (50.0–95.2) 73.4 (55.7–97.6) 0.5
HCG MOM 1.0 (0.7–1.6) 1.0 (0.8–1.3) 0.7
Data presented as median (interquartile range).
MOM, multiple of median.
Table 3 Serial angiogenic markers in pregnancy and pregnancy outcome
Time point of
measurement (EGA)
Angiogenic marker Preeclamptic
pregnancies (n = 19)
Normal
pregnancies (n = 408)
p-value
sFlt-1 4.1 (2.3–5.5) 5.4 (3.5–7.5) 0.03
8–10 weeks PlGF 24.1 (15.2–43.0) 20.7 (15.0–29.5 0.5
sFlt-1/PlGF ratio 155.3 (85.5–195.7) 235.3 (147.2–343.5) 0.002
sFlt-1 5.7 (3.2–9.2) 6.3 (3.9–9.0) 0.6
17–19 weeks PlGF 112.8 (81.7–175.6) 136.4 (100.5–192.7) 0.3
sFlt-1/PlGF ratio 35.8 (26.4–66.9) 47.1 (28.2–74.7) 0.6
sFlt-1 6.3 (3.0–9.7) 5.7 (3.9–8.9) 0.8
23–25 weeks PlGF 354.2 (182.6–583.1) 451.3 (303.9–651.0) 0.07
sFlt-1/PlGF ratio 13.9 (8.5–32.2) 12.6 (7.9–21.5) 0.2
sFlt-1 16.7 (9.0–26.7) 9.2 (6.4–13.7) 0.002
34–35 weeks PlGF 247.9 (102.2–589.9) 372.4 (186.1–707.1) 0.09
sFlt-1/PlGF ratio 74.0 (14.7–261.6) 25.3 (10.3–64.2) 0.03
Data presented as median (interquartile range).
sFlt-1 in ng/mL; PlGF in pg/mL; for calculation of sFlt-1/PlGF ratio, sFlt-1 was first converted to pg/mL.
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higher sFlt-1/PlGF ratio (Table 3).Association of dichotomized angiogenic markers with
pregnancy outcome
As first trimester sFlt-1 levels exhibited similar distribution
to PAPP-A MOM, these levels were also dichotomized as
<median (LowSFlt-1) or ≥median (HighSFlt-1) to deter-
mine if first trimester sFlt-1 levels could predict pregnancy
outcome. However, LowSFlt-1 was not significantly associ-
ated with decreased odds of normal pregnancy, OR 0.5,
[0.2, 1.4], nor was HighSFlt-1 significantly associated with
increased odds of normal pregnancy, OR 2.0, [0.7, 6.6].
In contrast, dichotomized sFlt-1/PlGF ratio was associ-
ated with pregnancy outcome. Specifically, low first tri-
mester sFlt-1/PLGF ratio (< median sFlt-1/PlGF ratio)
was significantly associated with decreased odds of nor-
mal pregnancy, OR 0.23, [0.05, 0.74], p = 0.01. High first
trimester sFlt-1/PLGF ratio (≥ median sFlt-1/PlGF ratio)
was associated with increased odds of normal pregnancy,
OR 4.29, [1.36, 18.94], p = 0.01.Table 4 Correlation of 1st trimester log PAPP-A MOM with
log sFlt-1 at serial time points (unadjusted)
Time point of sFlt-1
measurement (EGA)
Preeclamptic
pregnancies (n = 18)a
Normal
pregnancies(n = 405)b
8–10 weeks r = 0.35 p = 0.2 r = 0.26 p <0.0001
17–19 weeks r = 0.50 p = 0.05 r = 0.32 p <0.0001
23–25 weeks r = 0.33 p = 0.2 r = 0.27 p <0.0001
34–35 weeks r = 0.18 p = 0.5 r = 0.19 p = 0.0002
aFor PE pregnancies at time point 17–19 weeks, n = 16.
bFor normal pregnancies n = 382, 390 and 394 for time points 17–19 weeks,
23–25 weeks, and 34–35 weeks, respectively.
r, Pearson’s correlation coefficient.Correlation of PAPP-A with serial sFlt-1 levels
A significant positive correlation was observed between
log-transformed PAPP-A MOM and log sFlt-1 in women
with normal pregnancy. In these women, 1st trimester
PAPP-A MOM correlated positively with sFlt-1 at all
four time points during pregnancy (Table 4). For women
with preeclampsia, the correlation was also positive, but
only approached statistical significance at 17–19 weeks.
Log-transformed PAPP-A MOM was not significantly
associated with log PlGF (data not shown).Association of dichotomized PAPP-A MOM with serial
angiogenic markers
In the 1st trimester, women with low PAPP-A who had a
normal pregnancy (NlPreg-LowPAPPA) had similar sFlt-1
levels to women with low PAPP-A who developed pre-
eclampsia (PE-LowPAPPA), 4.9 ± 2.7 vs. 3.4 ± 1.8 ng/mL,
respectively (Figure 1). Similarly, in women with normal
pregnancy who had high PAPP-A (NlPreg-HighPAPPA),
1st trimester sFlt-1 did not differ significantly from women
with high PAPP-A levels who later developed preeclamp-
sia (PE-HighPAPPA), 6.9 ± 4.0 vs. 8.8 ± 3.2 ng/mL respec-
tively. There were significant differences in 1st trimester
sFlt-1 between NlPreg-LowPAPPA and NlPreg-HighPAP
PA, 4.9 ± 2.7 vs. 6.9 ± 4.0 ng/mL, respectively, p < 0.0001.
PE-LowPAPPA also had significantly lower 1st trimester
sFlt-1 compared with NlPreg-HighPAPPA (3.4 ± 1.8 vs.
6.9 ± 4.0 ng/mL, p = 0.0009).
At 17–19 weeks, PE-LowPAPPA women continued to
have lower sFlt-1 levels compared with PE-HighPAPPA
(5.5 ± 3.3 vs. 14.3 ± 4.9 ng/mL, p = 0.02), Figure 1. In ad-
dition, NlPreg-LowPAPPA women had significantly
Figure 1 Longitudinal sFlt-1 levels during pregnancy by PAPP-A status and pregnancy diagnosis. PAPP-A MOM levels were dichotomized:
low PAPP-A MOM (< median PAPP-A MOM) or high PAPP-A (≥ median PAPP-A MOM). A majority of women with preeclampsia were classified as
low PAPP-A MOM (PE-LowPAPPA). Women with PE-LowPAPPA had the greatest change in sFlt-1 levels between the 1st and 3rd trimesters,
compared with women with normal pregnancy, regardless of PAPP-A status (NLPreg-LowPAPPA and NLPreg-HighPAPPA, p < 0.02).
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(5.9 ± 3.0 vs. 8.6 ± 5.7, p < 0.0001) and also compared
with PE-HighPAPPA (5.9 ± 3.0 vs. 14.3 ± 4.9, p = 0.01).
This pattern remained at 23–25 weeks (Figure 1). At
34–35 weeks, sFlt-1 levels increased in all four groups,
increased to the greatest degree in PE-LowPAPPA
women (Figure 1). At this time point, there were signifi-
cant differences in sFlt-1 between NlPreg-LowPAPPA
and NlPreg-HighPAPPA (10.3 ± 8.2 vs. 13.2 ± 10.7, p = 0.02)
and NlPreg-LowPAPPA and PE-LowPAPPA (10.3 ± 8.2 vs.
17.2 ± 9.6, p = 0.04), Figure 1. Women with PE-LowPAPPA
had the greatest change in sFlt-1 levels between the 1st and
3rd trimesters, compared with NLPreg-LowPAPPA and
NLPreg-HighPAPPA (p < 0.02). Although PE-High PAPPA
women had the highest 3rd trimester sFlt-1 levels, due to
the small sample size, this level was not significantly differ-
ent than the other groups.
PlGF levels did not differ significantly between these
four groups (PE-LowPAPPA, PE-highPAPPA, NlPreg-
LowPAPPA, Nlpreg-HighPAPPA) at each of the four time
points (data not shown). However, sFlt-1/PlGF ratios did
vary significantly between the 4 groups and overall fol-
lowed a U-shaped pattern, with the greatest differences
observed at 8–10 weeks and 34–35 weeks (Figure 2). At
8–10 weeks, PE-LowPAPPA women had significantly
lower sFlt-1/PlGF ratio compared with NlPreg-LowPAPPA
(154 ± 93 vs. 232 ± 143, p = 0.03) and also compared with
NlPreg-HighPAPPA (154 ± 93 vs. 307 ± 206, p = 0.0006),
Figure 2. NlPreg-LowPAPPA women also had significantly
lower sFlt-1/PlGF ratio compared with NlPreg-HighPA
PPA women (232 ± 143 vs. 307 ± 206, p < 0.0001). By
34–35 weeks, however, PE-LowPAPPA women had the
highest sFlt-1/PlGF ratio, and this was significantly higher
than NlPreg-LowPAPPA (228 ± 331 vs. 77 ± 220, p = 0.03)and NlPreg-HighPAPPA (228 ± 331 vs. 79 ± 211, p = 0.04).
At this time point, no differences were observed in
sFlt-1/PlGF ratio between NlPreg-LowPAPPA and NlPreg-
HighPAPPA women.
Demographic characteristics of women with low first
trimester PAPP-A levels
There were no differences in age or parity by dichoto-
mized PAPP-A status. With respect to 1st trimester BMI,
women who developed preeclampsia had significantly
higher BMI, but this did not differ by PAPP-A status
(PE-LowPAPPA 29.5 ± 7.0 vs. PE-highPAPPA 29.4 ±
2.9 kg/m2 and NlPreg-LowPAPPA 25.4 ± 5.3 vs. NlPreg-
HighPAPPA 25.0 ± 5.0 kg/m2). Similarly, women with
preeclampsia had lower gestational age at delivery com-
pared with women with normal pregnancy, but this
did not differ by PAPP-A status (PE-LowPAPPA 38.4 ±
2.3 vs. PE-HighPAPPA 38.7 ± 0.6 weeks EGA and NlPreg-
LowPAPPA 39.3 ± 1.2 vs. NlPreg-HighPAPPA 39.4 ±
1.2 weeks EGA). MAP throughout pregnancy differed by
pregnancy outcome but not PAPP-A status, and was sig-
nificantly higher in women who developed preeclampsia
(data not shown).
In contrast, PAPP-A status was significantly associated
infant birth weight and the z-score of the birth weight,
which was adjusted for weeks EGA. The birth weights of
infants born to women with normal pregnancies differed
by PAPP-A status, and lower PAPP-A MOM was associ-
ated with lower birth weight (NlPreg-LowPAPPA 3.3 ±
0.4 vs. NlPreg-HighPAPPA 3.5 ± 0.4 kg, p = 0.001). Simi-
larly, the zscore of the birth weight, which was adjusted
for weeks EGA, was also lower in women with normal
pregnancy with low 1st PAPP-A (NlPreg-LowPAPPA
0.04 ± 0.8 vs. NlPreg-HighPAPPA 0.3 ± 0.8, p = 0.01). In
Figure 2 Longitudinal sFlt-1/PlGF ratios during pregnancy by PAPP-A status and pregnancy diagnosis. sFlt-1/PlGF ratios varied significantly
between the 4 groups and overall followed a U-shaped pattern, with the greatest differences observed at 8–10 weeks and 34–35 weeks. At 8–10 weeks,
PE-LowPAPPA women had significantly lower sFlt-1/PlGF ratio compared with NlPreg-LowPAPPA (p = 0.03) and also compared with NlPreg-HighPAPPA
(p = 0.0006). NlPreg-LowPAPPA women also had significantly lower sFlt-1/PlGF ratio compared with NlPreg-HighPAPPA women (p < 0.0001). By
34–35 weeks, however, PE-LowPAPPA women had the highest sFlt-1/PlGF ratio, and this was significantly higher than NlPreg-LowPAPPA (p = 0.03)
and NlPreg-HighPAPPA (p = 0.04). At this time point, no differences were observed in sFlt-1/PlGF ratio between NlPreg-LowPAPPA and
NlPreg-HighPAPPA women.
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infants with significantly lower birth weight, but this did
not differ according to PAPP-A status (PE-LowPAPPA
3.1 ± 0.8 vs. PE-HighPAPPA 3.0 ± 0.3 kg).
Discussion
Women who later developed preeclampsia demonstrated
significantly lower 1st trimester PAPP-A and PAPP-A
MOM compared with women with normal pregnancies,
as has been demonstrated previously [7]. Similarly, 1st
trimester sFlt-1 levels were significantly lower in women
with later preeclampsia, and were highest in these
women prior to delivery. sFlt-1/PLGF ratio followed a
similar pattern to sFlt in these women throughout preg-
nancy with the lowest 1st trimester ratio and highest 3rd
trimester ratio in women with later preeclampsia. Although
a positive correlation was observed between 1st trimester
PAPP-A MOM and serial sFlt-1 levels throughout preg-
nancy, this relationship only attained statistical significance
in women with normal pregnancy. PAPP-A levels were in-
dependent from other angiogenic factors and appeared to
be better than first trimester sFlt-1 in predicting preeclamp-
sia and at least as good as the first trimester sFlt-1/PlGF ra-
tio. Based on these results, it appears that measuring first
trimester sFlt-1 and/or PlGF would not improve the ability
to predict development of preeclampsia beyond informa-
tion obtained from first trimester PAPP-A levels.
Low PAPP-A MOM status (< median PAPP-A MOM)
predicted decreased odds of normal pregnancy, while
high PAPP-A status significantly predicted increased
odds of normal pregnancy. Despite its correlation to 1st
trimester PAPP-A, low 1st trimester sFlt-1 did not havethe same ability to predict pregnancy outcome. However,
the 1st trimester sFlt-1/PlGF ratio was able to predict
pregnancy outcome, though the predictive value was
slightly weaker than for PAPP-A MOM. Low PAPP-A
MOM status in women with normal pregnancy was also
associated with lower birth weight, both measured birth
weight and birth weight adjusted for gestational age.
Although PAPP-A levels have been measured to indi-
cate risk for trisomy 21, 18 and 13 [5], research suggests
that low levels also indicate risk of other pregnancy
complications, including preeclampsia [6,7]. Prior stud-
ies have demonstrated that the positive predictive value
of PAPP-A for preeclampsia is low [6,7], however they in-
cluded women with pre-gestational or gestational dia-
betes, which may have affected both PAPP-A levels and
pregnancy outcome. In contrast, our study focused on two
carefully selected populations and compared women with
confirmed normal pregnancies and with women with pre-
eclampsia, without gestational or pregestational diabetes.
During pregnancy, PAPP-A is synthesized and released
by the syncytiotrophoblast and maternal serum PAPP-A
levels increase throughout pregnancy [15]. PAPP-A is
thought to promote growth and development of the pla-
centa by increasing local bioavailability of insulin-like
growth factors 1 and 2 (IGF-1 and IGF-2) [16,17]. Inter-
estingly, low 1st trimester PAPP-A status in our subject
population predicted lower birth weight of babies born to
women with normal pregnancies, which supports findings
from previous studies [18].
Research suggests that excess placental production of
sFlt-1, a truncated splice variant of the VEGF receptor,
contributes to the development of preeclampsia. sFlt-1
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VEGF and PLGF [1]. sFlt-1 production is upregulated in
placenta of women with preeclampsia, leading to eleva-
tion of maternal serum sFlt-1 [19]. Increase in maternal
sFlt-1 precedes clinical signs of preeclampsia, and mater-
nal sFlt-1 levels correlate with disease severity [8]. How-
ever, published studies indicate an inconsistent relationship
between maternal 1st trimester sFlt-1 levels and develop-
ment of preeclampsia, with some studies showing that 1st
trimester levels are increased in preeclampsia [20-22] and
other studies demonstrating no differences in 1st trimester
sFlt-1 levels between patients who developed preeclampsia
and those who had normal pregnancy [23,24]. To our
knowledge, only two other published studies has presented
sFlt-1 data as early as 8 weeks in pregnancy, and these stud-
ies also reported significantly lower sFlt-1 levels in pregnan-
cies that later developed preeclampsia [4,25].
One other publication explored the relationship of 1st
trimester PAPP-A with 1st trimester sFlt-1 in preeclamp-
sia and normal pregnancies [26]. In that population,
PAPP-A MOM levels were lower in women who later
developed preeclampsia, similar to our own findings, but
sFlt-1 MOM levels were higher in women who devel-
oped preeclampsia. That study examined women later in
pregnancy than our study (12 weeks EGA vs. 8–10 weeks
EGA in our study), and did not measure sFlt-1 levels in
the 2nd and 3rd trimesters, when the rise in sFlt-1 has
been shown to be significantly associated with the devel-
opment of preeclampsia. In addition, in this paper, we
report measured sFlt-1 levels, rather than sFlt-1 MOM
levels, as our subjects completed laboratory measure-
ments at specific, narrow time points. Furthermore,
while it is accepted practice to measure PAPP-A in
terms of MOM adjusted for gestational age and maternal
weight [5], the appropriateness for this type of adjust-
ment of sFlt-1 is less clear with most published studies
reporting measured sFlt-1 levels, rather than MOM.
Our study did not find a significant relationship be-
tween 1st trimester PAPP-A levels and serial PlGF levels
throughout pregnancy. Other studies have examined the
ability of PAPP-A and PlGF in combined models to pre-
dict preeclampsia, with some reporting a relationship be-
tween these two factors [27] and other not reporting a
relationship [26]. As both PAPP-A and PlGF are thought
to be involved in placental growth and development, one
might expect that their levels would correlate. Based on
our data, however, it appears that PAPP-A levels follow
a similar pattern in early pregnancy to sFlt-1.
There may be multiple connections linking PAPP-A and
sFlt-1 to each other and to preeclampsia. Both PAPP-A
and sFlt-1 are produced by vascular smooth muscle cells
[28,29] and may serve as markers of maternal or placental
vascular dysfunction. Also, the placental renin-angiotensin-
aldosterone system (RAAS) may be a common factorconnecting PAPP-A and sFlt-1 to the pathophysiology of
preeclampsia. During pregnancy, circulating PAPP-A is
largely bound to the proform of Major Basic Protein
(ProMBP) [30], which also forms a covalent complex with
angiotensinogen [31]. This form of angiotensinogen is the
predominant form identified in patients with preeclampsia
[32]. It has been speculated that the formation of the
ProMBP-PAPPA complex and formation of ProMBP-angio
tensinogen complex may be competing reactions [32,33].
Research indicates that sFlt-1 is produced with RAAS acti-
vation, as pregnant mouse models have shown that infused
Angiotensin II (Ang II) regulates sFlt-1 production via acti-
vation of the Ang II receptor Type 1 (AT1 receptor) [34].
As a result, it seems similar patterns in PAPP-A and sFlt-1
levels in pregnancy may reflect their common connections
to maternal or placental vascular dysfunction or the pla-
cental RAAS.
This paper has several strengths. All subjects were
studied at multiple, pre-specified time points throughout
all three trimesters of pregnancy. The diagnosis of pre-
eclampsia was confirmed in each subject by expert panel
review of the medical record. Furthermore, all subjects
were healthy prior to pregnancy, with no other signifi-
cant medical diagnoses, such as gestational diabetes, that
may have predisposed them to pregnancy complications.
In addition, serial angiogenic markers were obtained in
each subject at all time points to establish a pattern of
angiogenic markers throughout pregnancy.
There were some limitations for this study as well.
The number of cases of preeclampsia was relatively low,
but represented 4% of the total study sample in this ana-
lysis, which is consistent with other studies and the
reported prevalence of preeclampsia [1]. Many of the
subjects in this study delivered after 37 weeks EGA,
which may represent a different severity or phenotype of
preeclampsia than other published studies. In addition,
as PAPP-A levels were obtained solely for the purpose of
1st trimester screening, serial PAPP-A levels throughout
pregnancy were not available for analysis. It would have
been interesting to explore the relationship of PAPP-A
levels in the 2nd and 3rd trimesters with sFlt-1 levels at
those time points, but that data were not available.
Conclusions
Both 1st trimester PAPP-A levels and sFlt-1 levels were
significantly lower in women who later developed pre-
eclampsia. 1st trimester PAPP-A levels were significantly
correlated with serial sFlt-1 levels measured longitudi-
nally throughout pregnancy. Furthermore, low PAPP-A
status in the 1st trimester significantly predicted de-
creased odds of normal pregnancy.
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